Advertisement

Topics

Latest "The Fondation IPSEN" News Stories

04:10 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "The Fondation IPSEN" found in our extensive news archives from over 250 global news sources.

More Information about The Fondation IPSEN on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about The Fondation IPSEN for you to read. Along with our medical data and news we also list The Fondation IPSEN Clinical Trials, which are updated daily. BioPortfolio also has a large database of The Fondation IPSEN Companies for you to search.

Showing "Fondation IPSEN" News Articles 1–25 of 134

Friday 15th February 2019

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.   


AZ And Ipsen Outline Brexit Contingency Plans

With the UK no nearer to deciding how hard or soft its exit from the EU will be on March...    

Thursday 14th February 2019

Chinese patients to get new drugs before UK after Brexit - says CEO

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview. David Meek spoke to pharmaphorum ahead of the company’s full year results anno...


Ipsen S.A. ADR 2018 Q4 - Results - Earnings Call Slides

Ipsen Delivers Strong 2018 Results and Expects Continued Sales and Profit Growth in 2019

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its financial results for the full year 2018. Extract of audited consolidated results for the full year 2018 and 2017 ...

Wednesday 13th February 2019

Ipsen expects to hit 2020 revenue guidance early

Tuesday 12th February 2019

Exelixis Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

- Total Revenue of $228.6 million for the Fourth Quarter of 2018, $853.8 million for the Full Year 2018 - - Cabozantinib Franchise Net Product Revenue of $176.2 million for the Fourth Quarter of 2018, $619.3 million for the Full Year 2018 - - GAAP Diluted EPS of $1.15 for the Fourth Quarter of 2018, $2.21 for the Full Year 2018 - ...

Wednesday 30th January 2019

Global Botox Injection Market Data Survey Report 2025 [Report Updated: 01011970] Prices from USD $1500

SummaryThe global Botox Injection market will reach Volume Million USD in 2018 with CAGR xx% 20182025. The main contents of the report including:Global market size and forecastRegional market size, production data and export importKey manufacturers manufacturing sites, capacity and production, product specifications etc.Major ApplicationMajor TypeKey manufacturers are included based on manufactur...

Here Are Some Biotech Jobs to Owl About

Hello biotechnologists, Job hunt frustrating? Don’t worry, we’re here to help. Check out the position as R&D Manager at Ipsen or become a Business Executive at Clintec. Just starting out? Check out the internship at Artios! Research and Development Manager Cell Line Engineering ... The post Here Are Some Biotech Jobs to Owl About appeared first on Labiotech.eu.

Tuesday 29th January 2019

SmartPeople: Dr Alexandre Lebeaut

Ipsen’s Alexandre Lebeaut discusses the highs and lows of working in pharmaceutical research and development.

Wednesday 23rd January 2019

PeptiDream Announces New Peptide Drug Conjugate (PDC) Discovery Deal with Shionogi

PeptiDream Inc., a public Kanagawa-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that it has entered into a multi-program collaborative research agreement with Osaka-based Shionogi & Co., Ltd (“Shionogi”)(TOKYO:4507) for the discovery and development of a series of blood brain barrier (BBB) penetrating peptide drug-...

Friday 18th January 2019

Survey shows efficacy of BoNT-A treatment for spasticity

An international survey conducted by biopharmaceutical group Ipsen and social media platform Carenity found a significant hidden burden associated with...Read More... The post Survey shows efficacy of BoNT-A treatment for spasticity appeared first on Pharmaceutical Technology.

Ipsen: Patients Living with Spasticity Want Long-lasting Symptom Relief

International survey presented at TOXINS 2019 reveals hidden burden of spasticity1 Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190117005697/en/ Carenity Infographic Ipsen (Euronext: IPN; ADR: IPSEY) today presents at TOXINS, results from an international s...

Thursday 17th January 2019

Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019

Safety, tolerability and pharmacodynamics of BoNT-E demonstrated in Phase I study1 Regulatory News: Results of the first in-human study of a recombinant neurotoxin are being presented at the TOXINS International Conference in Copenhagen. Ipsen’s recombinant BoNT serotype E (rBoNT-E) was investigated in a phase I study that demonstrate...

Monday 14th January 2019

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

– Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial – – Exelixis prepared to fully support new indication immediately – Exelixis, Inc. (NASDAQ:EXEL) today announced that the U.S. Food and Drug Administration (

Friday 11th January 2019

Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that abobotulinumtoxinA (Dysport®) and its recombinant botulinum toxins pipeline are the subject of 50 posters at the 2019 TOXINS International Conference. Results are presented from basic science (in vivo, in vitro, ex vivo, in silico), to clinical (Phase I to IV) and pati...

Thursday 10th January 2019

Ipsen (IPSEF) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow

Sunday 6th January 2019

Active Biotech AB ACTI Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryActive Biotech AB Active Biotech is a biotechnology company that develops and commercializes pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company's key products in development include Laquinimod neurodegenerative diseases; Anyara cancer; Tasquinimod cancer; Paquinimod Systemic Sclerosis; and SILC autoimmune diseases. It has licensing agreements wit...

Friday 4th January 2019

Longitude takes a spin with Cydan

Why Longitude backed Cydan spinout Tiburio Therapeutics to repurpose an Ipsen Group asset for a rare neuroendocrine tumor.

Thursday 3rd January 2019

Cydan Announces Formation of Tiburio Therapeutics Inc. to Develop Treatments for Rare Neuroendocrine Tumors and Endocrine Diseases

Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases Tiburio appoints Abraham N. Ceesay as Chief Executive Officer Cydan today announced the launch of Tiburio Therapeutics Inc. (Tiburio), ...

Wednesday 2nd January 2019

Cydan spins out rare endocrine company Tiburio with $31M, Ipsen compounds

Tiburio Launches with $31 Million and Two Compounds from Ipsen Targeting Rare Endocrine Diseases

New biotech Tiburio has surged onto the scene with $31 million in financing and two novel Phase II-ready assets licensed from Ipsen Pharma. The new company, spun out of orphan drug accelerator Cydan is focused on rare endocrine diseases.

Wednesday 19th December 2018

Gossamer Bio Announces Appointment of New Independent Directors

Gossamer Bio, Inc., a privately held, clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the appointment of Joshua H. Bilenker, M.D., Russell J. Cox and Renée Galá to its Board of Directors. Ms. Galá ...

Friday 14th December 2018

Ipsen warns over medicine supplies amid Brexit uncertainty

France’s Ipsen has become the latest pharma company to warn about the impact of Brexit on the pharma industry and patients’ access to medicines. As Theresa May attempts to drum up support for her Brexit deal, the French pharma said it was taking s...

Wednesday 12th December 2018

Synlogic Expands Capabilities in Manufacturing with the Appointment of Head of Technical Operations and Establishment of In-house Production of Clinical Trial Material for its Synthetic BioticTM Medicines

– Good Manufacturing Process (GMP) infrastructure enables advancement of clinical programs through early and mid-phase studies – – Capabilities support production of both liquid and solid oral formulations – Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage drug discovery and development company applying synthetic biology to benefic...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks